-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。Valeの第1四半期決算は、調整後EBITDAが39億ドル(前年同期比21%増)、売上高が93億ドル(前年同期比14%増)と、まちまちの結果となりました。売上高は市場予想を2億3,700万ドル下回り、調整後EPSは0.44ドルで、市場予想を0.06ドル下回りました。季節的な支出による運転資金の逆風にもかかわらず、フリーキャッシュフローは8億1,300万ドル(前年同期比61%増)に達しました。非鉄金属部門は、EBITDAが12億ドル(前年同期比116%増)に急増し、特に銅部門のEBITDAは9億4,900万ドル(前年同期比74%増)と好調でした。これは、市場の逼迫と販売価格の上昇が要因です。経営陣は、ブラジルレアルの対米ドル高を背景に、2026年のコストガイダンスはレンジの上限に向かっていると示唆しました。鉄鉱石は、主に為替変動の影響でC1コストが23.60ドル/トン(前年比+12%)に上昇し、利益率への圧力に直面しているものの、販売量は5940万トン(前年比+5%)と堅調に推移している。バランスシートは健全で、純負債は136億ドル、レバレッジは過去12ヶ月間の調整後EBITDAの0.8倍に抑えられている。ヴァーレの多角的な事業ポートフォリオは回復力をもたらし、非鉄金属事業の強みが短期的には鉄鉱石の利益率低下を相殺すると考えている。
Related Articles
Research Alert: Gsk Q1 Beat As Specialty Medicines Remains Strong, Reiterates 2026 Outlook
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GSK delivered a Q1 2026 beat with sales growing 2% Y/Y (5% CER), led by Specialty Medicines (+10% or +14% CER), particularly oncology with strong Jemperli and Ojjaara uptake, while Vaccines grew 4% CER on record Shingrix sales. Core EPS grew 4% or 9% CER to GBP0.465, ahead of the consensus of GBP0.44, supported by a favorable product mix and cost control that lifted the core operating margin by 1.0%-pt or 1.8%-pts CER. We view the Q1 update positively given the beat and margin expansion, though we are mindful of currency headwinds. GSK reiterated its 2026 guidance for 3%-5% sales growth and 7%-9% core operating profit growth (CER), which is broadly aligned with that of several peers like Sanofi and Roche despite implying slower growth versus 2025. We expect revenue to be supported by key Specialty Medicines products, with GSK targeting the segment to contribute more than 50% of sales by 2031 (Q1 2026: 42%), while recent acquisitions provide a much-needed boost to growth and the drug pipeline, in our view.
Gamuda Unit Bags Nearly MYR6 Billion Project from Sabah State Water Department
Gamuda (KLSE:GAMUDA) unit Upper Padas Power received a Letter of Acceptance worth 5.98 billion ringgit from the Sabah State Water Department for Phase 1 of the Skim Bekalan Air Ulu Padas.The project forms a bolt-on development linked to the Ulu Padas Hydroelectric Project and is designed to strengthen water supply for Sabah's west coast, according to a Wednesday Malaysian bourse filing.Phase 1 involves the construction of a 350 million litres per day water treatment plant in Beaufort, along with about 200km of pipelines stretching from Sipitang to Kota Kinabalu.The project marks a key infrastructure expansion alongside its hydroelectric development in Sabah, Malaysia, the company said.
Aker Solutions to Develop Framed Modules Components for Rolls-Royce SMR
Aker Solutions (AKSO.OL) secured a deal to develop non-nuclear parts of framed modules for Rolls-Royce (RR.L) unit Rolls-Royce SMR, according to a Wednesday release.Under a memorandum of understanding, the Norwegian energy-focused engineering group will work with Rolls-Royce SMR to define the design and scope, and modularization approach for customer projects in the UK and other countries, with an initial focus on the UK and the Czech Republic.